ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial [Yahoo! Finance]
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update [Yahoo! Finance]
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Life Sciences Investor Forum Agenda Announced for November 14th